Cargando…
Synthesis and broad spectrum antiviral evaluation of bis(POM) prodrugs of novel acyclic nucleosides
A series of seventeen hitherto unknown ANP analogs bearing the (E)-but-2-enyl aliphatic side chain and modified heterocyclic base such as cytosine and 5-fluorocytosine, 2-pyrazinecarboxamide, 1,2,4-triazole-3-carboxamide or 4-substituted-1,2,3-triazoles were prepared in a straight approach through a...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Masson SAS. Published by Elsevier Masson SAS
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111275/ https://www.ncbi.nlm.nih.gov/pubmed/23911854 http://dx.doi.org/10.1016/j.ejmech.2013.06.053 |
_version_ | 1783513252846632960 |
---|---|
author | Hamada, Manabu Roy, Vincent McBrayer, Tamara R. Whitaker, Tony Urbina-Blanco, Cesar Nolan, Steven P. Balzarini, Jan Snoeck, Robert Andrei, Graciela Schinazi, Raymond F. Agrofoglio, Luigi A. |
author_facet | Hamada, Manabu Roy, Vincent McBrayer, Tamara R. Whitaker, Tony Urbina-Blanco, Cesar Nolan, Steven P. Balzarini, Jan Snoeck, Robert Andrei, Graciela Schinazi, Raymond F. Agrofoglio, Luigi A. |
author_sort | Hamada, Manabu |
collection | PubMed |
description | A series of seventeen hitherto unknown ANP analogs bearing the (E)-but-2-enyl aliphatic side chain and modified heterocyclic base such as cytosine and 5-fluorocytosine, 2-pyrazinecarboxamide, 1,2,4-triazole-3-carboxamide or 4-substituted-1,2,3-triazoles were prepared in a straight approach through an olefin acyclic cross metathesis as key synthetic step. All novel compounds were evaluated for their antiviral activities against a large number of DNA and RNA viruses including herpes simplex virus type 1 and 2, varicella zoster virus, feline herpes virus, human cytomegalovirus, hepatitis C virus (HCV), HIV-1 and HIV-2. Among these molecules, only compound 31 showed activity against human cytomegalovirus in HEL cell cultures with at EC(50) of ∼10 μM. Compounds 8a, 13, 14, and 24 demonstrated pronounced anti-HCV activity without significant cytotoxicity at 100 μM. |
format | Online Article Text |
id | pubmed-7111275 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Elsevier Masson SAS. Published by Elsevier Masson SAS |
record_format | MEDLINE/PubMed |
spelling | pubmed-71112752020-04-02 Synthesis and broad spectrum antiviral evaluation of bis(POM) prodrugs of novel acyclic nucleosides Hamada, Manabu Roy, Vincent McBrayer, Tamara R. Whitaker, Tony Urbina-Blanco, Cesar Nolan, Steven P. Balzarini, Jan Snoeck, Robert Andrei, Graciela Schinazi, Raymond F. Agrofoglio, Luigi A. Eur J Med Chem Original Article A series of seventeen hitherto unknown ANP analogs bearing the (E)-but-2-enyl aliphatic side chain and modified heterocyclic base such as cytosine and 5-fluorocytosine, 2-pyrazinecarboxamide, 1,2,4-triazole-3-carboxamide or 4-substituted-1,2,3-triazoles were prepared in a straight approach through an olefin acyclic cross metathesis as key synthetic step. All novel compounds were evaluated for their antiviral activities against a large number of DNA and RNA viruses including herpes simplex virus type 1 and 2, varicella zoster virus, feline herpes virus, human cytomegalovirus, hepatitis C virus (HCV), HIV-1 and HIV-2. Among these molecules, only compound 31 showed activity against human cytomegalovirus in HEL cell cultures with at EC(50) of ∼10 μM. Compounds 8a, 13, 14, and 24 demonstrated pronounced anti-HCV activity without significant cytotoxicity at 100 μM. Elsevier Masson SAS. Published by Elsevier Masson SAS 2013-09 2013-07-04 /pmc/articles/PMC7111275/ /pubmed/23911854 http://dx.doi.org/10.1016/j.ejmech.2013.06.053 Text en Copyright © 2013 Elsevier Masson SAS. Published by Elsevier Masson SAS All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Article Hamada, Manabu Roy, Vincent McBrayer, Tamara R. Whitaker, Tony Urbina-Blanco, Cesar Nolan, Steven P. Balzarini, Jan Snoeck, Robert Andrei, Graciela Schinazi, Raymond F. Agrofoglio, Luigi A. Synthesis and broad spectrum antiviral evaluation of bis(POM) prodrugs of novel acyclic nucleosides |
title | Synthesis and broad spectrum antiviral evaluation of bis(POM) prodrugs of novel acyclic nucleosides |
title_full | Synthesis and broad spectrum antiviral evaluation of bis(POM) prodrugs of novel acyclic nucleosides |
title_fullStr | Synthesis and broad spectrum antiviral evaluation of bis(POM) prodrugs of novel acyclic nucleosides |
title_full_unstemmed | Synthesis and broad spectrum antiviral evaluation of bis(POM) prodrugs of novel acyclic nucleosides |
title_short | Synthesis and broad spectrum antiviral evaluation of bis(POM) prodrugs of novel acyclic nucleosides |
title_sort | synthesis and broad spectrum antiviral evaluation of bis(pom) prodrugs of novel acyclic nucleosides |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111275/ https://www.ncbi.nlm.nih.gov/pubmed/23911854 http://dx.doi.org/10.1016/j.ejmech.2013.06.053 |
work_keys_str_mv | AT hamadamanabu synthesisandbroadspectrumantiviralevaluationofbispomprodrugsofnovelacyclicnucleosides AT royvincent synthesisandbroadspectrumantiviralevaluationofbispomprodrugsofnovelacyclicnucleosides AT mcbrayertamarar synthesisandbroadspectrumantiviralevaluationofbispomprodrugsofnovelacyclicnucleosides AT whitakertony synthesisandbroadspectrumantiviralevaluationofbispomprodrugsofnovelacyclicnucleosides AT urbinablancocesar synthesisandbroadspectrumantiviralevaluationofbispomprodrugsofnovelacyclicnucleosides AT nolanstevenp synthesisandbroadspectrumantiviralevaluationofbispomprodrugsofnovelacyclicnucleosides AT balzarinijan synthesisandbroadspectrumantiviralevaluationofbispomprodrugsofnovelacyclicnucleosides AT snoeckrobert synthesisandbroadspectrumantiviralevaluationofbispomprodrugsofnovelacyclicnucleosides AT andreigraciela synthesisandbroadspectrumantiviralevaluationofbispomprodrugsofnovelacyclicnucleosides AT schinaziraymondf synthesisandbroadspectrumantiviralevaluationofbispomprodrugsofnovelacyclicnucleosides AT agrofoglioluigia synthesisandbroadspectrumantiviralevaluationofbispomprodrugsofnovelacyclicnucleosides |